“We are on track to complete enrollment of 80 patients treated with single agent envafolimab in the ongoing pivotal ENVASARC trial this year. The data monitoring committee recommended the study continue as planned in September based on a review of 46 patients and since then more than 20 additional patients have enrolled. We expect to report updated response rate data before the end of the year, with final data anticipated mid-2024,” said Charles Theuer, Tracon’s CEO. “We also expect to license our Product Development Platform to one or more companies this year to allow them to transform their clinical operations.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TCON:
- TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- TCON Upcoming Earnings Report: What to Expect?
- TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
- TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
- Tracon announces ENVASARC Phase 2 trial exceeded futility threshold
